Skye Bioscience Highlights Attributes of its Peripherally-restricted CB1 Inhibitor Antibody at Keystone Obesity Conference

Skye Bioscience presented preclinical data on nimacimab, a CB1 receptor inhibitor antibody, showing significant additive weight loss effects when combined with tirzepatide and semaglutide in diet-induced obesity mouse models. The drug demonstrated durable weight loss after treatment discontinuation and reduced weight rebound by ~80% when used as maintenance therapy post-tirzepatide discontinuation. Skye is currently conducting a Phase 2a clinical trial combining nimacimab with GLP-1R agonists.

01/29/2026, 7:00 AM • GlobeNewswire

Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Skye Bioscience, Inc.(SKYE) Shareholders

Levi & Korsinsky has filed a securities class action lawsuit against Skye Bioscience, Inc. on behalf of shareholders who suffered losses between November 4, 2024 and October 3, 2025. The complaint alleges that defendants made false statements about the effectiveness of the company's lead product candidate, nimacimab, and overstated its clinical, regulatory, and commercial prospects. Investors who suffered losses during this period can request to be appointed as lead plaintiff by January 16, 2026.

01/15/2026, 7:00 PM • GlobeNewswire

SKYE DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Skye Bioscience, Inc. Investors to Secure Counsel Before Important January 16 Deadline in Securities Class Action – SKYE

Rosen Law Firm is reminding investors who purchased Skye Bioscience securities between November 4, 2024 and October 3, 2025 of the January 16, 2026 lead plaintiff deadline in an ongoing securities class action. The lawsuit alleges that defendants made materially false and misleading statements regarding the effectiveness of nimacimab and overstated its clinical, regulatory, and commercial prospects.

01/15/2026, 2:58 PM • GlobeNewswire

JYD DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Jayud Global Logistics Ltd. Investors to Secure Counsel Before Important January 20 Deadline in Securities Class Action - JYD

Rosen Law Firm is reminding investors in Jayud Global Logistics Ltd. (JYD), Skye Bioscience, Inc. (SKYE), and Klarna Group plc (KLAR) of upcoming lead plaintiff deadlines in securities class action lawsuits. The firm is encouraging affected investors to secure legal counsel to potentially recover losses from alleged fraudulent activities and misleading statements.

01/15/2026, 2:50 PM • GlobeNewswire

Portnoy Law Firm Announces Class Action on Behalf of Skye Bioscience, Inc. Investors

Skye Bioscience investors are being advised of a class action lawsuit covering the period from November 4, 2024 to October 3, 2025. The action follows Skye's October 6, 2025 announcement that its nimacimab drug failed to achieve the primary endpoint of weight loss compared to placebo in a Phase 2a study, with lower than expected drug exposure. The stock price fell 60% to $1.90 per share on the news.

01/14/2026, 1:33 PM • GlobeNewswire

SKYE DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Skye Bioscience, Inc. Investors to Secure Counsel Before Important January 16 Deadline in Securities Class Action – SKYE

Rosen Law Firm is reminding investors in Skye Bioscience, Inc. (NASDAQ: SKYE) of the January 16, 2026 deadline to join a securities class action lawsuit. The lawsuit alleges that defendants made materially false and misleading statements regarding the effectiveness of nimacimab and overstated its clinical, regulatory, and commercial prospects, causing investor damages when the true details emerged.

01/12/2026, 8:15 PM • GlobeNewswire

Skye Bioscience, Inc. (NASDAQ: SKYE) Securities Class Action: Johnson Fistel Reminds Investors of January 16 Deadline to Seek Lead Plaintiff Appointment

Johnson Fistel announces a class action lawsuit against Skye Bioscience for investors who purchased securities between November 4, 2024 and October 3, 2025. The lawsuit alleges the company made materially false and misleading statements about its drug candidate nimacimab, overstating its effectiveness and commercial prospects. Investors must seek lead plaintiff appointment by January 16, 2026.

01/12/2026, 3:53 PM • GlobeNewswire

SKYE FINAL DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Skye Bioscience, Inc. Investors to Secure Counsel Before Important January 16 Deadline in Securities Class Action – SKYE

Rosen Law Firm is reminding investors in Skye Bioscience, Gauzy Ltd., and Stride, Inc. of upcoming lead plaintiff deadlines in securities class action lawsuits. The lawsuits allege that defendants made materially false and misleading statements regarding their business operations and prospects. Investors who purchased securities during specified class periods may be entitled to compensation.

01/09/2026, 5:34 PM • GlobeNewswire

LRN DEADLINE: ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Stride, Inc. Investors to Secure Counsel Before Important January 12 Deadline in Securities Class Action – LRN

Rosen Law Firm is notifying investors about securities class action lawsuits, with a January 12, 2026 deadline for lead plaintiff claims in the Stride, Inc. case. The lawsuit alleges that Stride made misleading statements about its products and services while inflating enrollment numbers, cutting staff costs improperly, and ignoring compliance requirements, resulting in investor damages.

01/09/2026, 5:28 PM • GlobeNewswire

ROSEN, A TOP RANKED LAW FIRM, Encourages Skye Bioscience, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SKYE

Rosen Law Firm is reminding investors who purchased Skye Bioscience securities between November 4, 2024 and October 3, 2025 of the January 16, 2026 lead plaintiff deadline in an ongoing securities class action. The lawsuit alleges that defendants made materially false and misleading statements regarding nimacimab's effectiveness and commercial prospects, causing investor damages when the truth entered the market.

01/01/2026, 12:20 PM • GlobeNewswire

SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit with the Schall Law Firm

The Schall Law Firm has filed a securities fraud class action lawsuit against Skye Bioscience, Inc. for making false and misleading statements about its drug candidate nimacimab, which proved less effective than claimed. Investors who purchased securities between November 4, 2024 and October 3, 2025 are encouraged to join the lawsuit by January 16, 2026.

01/01/2026, 11:59 AM • GlobeNewswire

ROSEN, A TOP-RANKED LAW FIRM, Encourages Skye Bioscience, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SKYE

Rosen Law Firm is reminding investors who purchased Skye Bioscience securities between November 4, 2024 and October 3, 2025 of the January 16, 2026 lead plaintiff deadline in an ongoing securities class action. The lawsuit alleges that defendants made materially false and misleading statements regarding the effectiveness and prospects of their drug nimacimab, causing investor damages when the truth entered the market.

12/29/2025, 8:08 PM • GlobeNewswire

SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit with the Schall Law Firm

The Schall Law Firm has filed a securities fraud class action lawsuit against Skye Bioscience, Inc. (NASDAQ: SKYE) for allegedly making false and misleading statements about its drug candidate nimacimab, overstating its commercial and clinical prospects. Investors who purchased securities between November 4, 2024 and October 3, 2025 are encouraged to join the lawsuit by January 16, 2026.

12/29/2025, 10:45 AM • GlobeNewswire

ROSEN, LEADING INVESTOR COUNSEL, Encourages Skye Bioscience, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SKYE

Rosen Law Firm is encouraging investors in Skye Bioscience, SLM Corporation (Sallie Mae), and Tandem Diabetes Care to join securities class action lawsuits. The firm alleges that Skye Bioscience made materially false statements regarding the effectiveness and prospects of its drug nimacimab. Investors who purchased securities during specified class periods may be eligible for compensation, with a January 16, 2026 deadline to serve as lead plaintiff.

12/26/2025, 5:23 PM • GlobeNewswire

SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Skye Bioscience

Law firm Faruqi & Faruqi is investigating potential securities fraud claims against Skye Bioscience following the company's announcement that its drug nimacimab failed to meet primary endpoints in a Phase 2a clinical trial. The disclosure of lower-than-expected drug exposure and failure to achieve weight loss compared to placebo resulted in a 60% stock price decline on October 6, 2025. Investors who purchased securities between November 4, 2024 and October 3, 2025 are encouraged to contact the firm, with a January 16, 2026 deadline to seek lead plaintiff status.

12/26/2025, 10:47 AM • GlobeNewswire